Auna Slashes 2026 EBITDA Outlook to Flat on Colombia Cost Spike
AUNA sits 31% above its 52-week low of $4.09.
Summary
Auna cut its 2026 Adjusted EBITDA guidance to roughly flat year over year, down from prior guidance of 10%-14% FX-neutral growth. Revenue growth is still tracking in line with prior guidance, so the problem is profitability, not sales. The culprit is a Colombia payor contract where higher-than-expected advanced-cancer incidence is driving care costs; management calls the pressure temporary but gives no quantification or normalization timeline. This follows the August 18 6-K, which already showed Q2 Adjusted EBITDA down 6% to S/227M despite revenue up 13% — the margin squeeze is now a full-year problem. Mexico recovery and reaffirmed capex near 4% of revenue support the top line, and favorable free cash flow and leverage trends cushion the balance sheet, but the earnings power reset is the story. Q3 results should clarify the Colombia contract impact and any path back to growth.
At the time of this announcement, AUNA was trading at $5.34 on NYSE in the Life Sciences sector, with a market capitalization of approximately $400.4M. The 52-week trading range was $4.09 to $6.71. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.